Samsung Bioepis releases Q2 2024 U.S. biosimilar market reportAs of April 2024, the FDA has approved a total of 48 biosimilars across 15 unique biological molecules, and of the 48 approvals, 38 biosimilars have launched in the U.S. market, per the report. Aetna Better Health of Michigan recommended for CHCP contractThe Comprehensive Health Care Program covers support of populations eligible for a variety of programs. Lupin gets approval for generic Ingrezza, launches generic Oracea Lupin is one of the first ANDA applicants for generic Ingrezza and is eligible for 180 days of shared generic exclusivity. Two CVS pharmacies in Rhode Island file to unionize Pharmacy professionals at a CVS in Las Vegas are set to have a union election April 24. Bausch wins U.S. appeal to block Norwich’s generic Xifaxan Norwich’s ANDA for Xifaxan 550 mg remains barred from approval by the Food and Drug Administration until Oct. 2, 2029. NACDS highlights Kroger’s participation in NACDS RxIMPACT The organization sat down with Colleen Lindholz, president of Kroger Health, to discuss the company's involvement in NACDS RxIMPACT grassroots programs. Opill, WNBA announce partnership The partnership aims to redefine contraception accessibility. Watch DSN: Walmart Canada reaffirms commitment to accessibility, affordability in healthcare Alex Hurd, VP, healthcare services at Walmart Canada, discusses the differences between retail pharmacy in Canada and the United States. CHPA taps Michael Bailey as senior VP, regulatory & scientific affairs Bailey will oversee all aspects of regulatory and scientific affairs at the organization. Baxter intros 5 new generic injectables The new products feature ready-to-use formulations to help support patient safety. First Previous 48 49 50 51 52 Next Last